On the morning of March 17th, the unveiling ceremony of the company's drug research institute was held in the newly built R&D building at the Liuyang base. Cai Xinya, Vice General Manager of Xingxiang Group, Secretary of the Company's Party Branch, and Chairman, attended the ceremony and delivered a speech. The company's middle-level and above management personnel, as well as all employees of the Drug Research Institute, attended the unveiling ceremony to witness this important moment together. The unveiling ceremony was presided over by Shen Fanshun, General Manager of the company.

Ouyang Xiye, President of the Institute of Materia Medica, introduced the work plan of the Institute during the 14th Five Year Plan period. He stated that in the future, the company will use the Institute of Materia Medica as a carrier, meet market demand, serve the company's strategy, fully leverage scientific research advantages, talent advantages, strategic advantages, and resource advantages, continuously enhance new drug research and development capabilities, adhere to innovation leading development, and strive to build the Institute of Materia Medica into a first-class research and development institution with flexible mechanisms, full of vitality, sound systems, and efficient work within the next three years.

Shen Fanshun presided over the unveiling ceremony and expressed his hope for a bright future for the Drug Research Institute. He pointed out that in the future, the company should rely on the Drug Research Institute to accelerate the product layout of "Chinese medicine ultrafine decoction pieces+Chinese medicine formula granules+Chinese medicine formulations+big health products"; By establishing a market-oriented, down-to-earth, and dynamic mechanism, we aim to build an excellent R&D team that matches the company's future development needs, providing a source of wisdom and strength for the company to become a leading enterprise in the traditional Chinese medicine industry.

Cai Xinya delivered a speech and put forward four requirements for the future development of the Drug Research Institute: firstly, research work should closely follow the company's strategic development plan, aim at the company's "14th Five Year Plan" strategic development goals, and research results should provide strong support for the company's development; Secondly, the research direction should be linked to policy guidelines, and timely research should be conducted on the national policies for the development of traditional Chinese medicine and the practical work needs to support the regional development of traditional Chinese medicine in Hunan Province, proposing actionable target recommendations; Thirdly, research results should meet market needs, and practical and feasible annual research plans should be formulated to strive for multi-level research results; Fourthly, research and development should be combined with talent policies, and the construction of the college's talent team should be effectively strengthened. Efforts should be made to introduce and cultivate high-level professional talents, fundamentally achieving continuous improvement in research level.

The establishment of a drug research institute by the company is not simply a matter of changing the name of the "R&D center". It is a reflection of the company's high emphasis on product research and innovation development, and a major measure to continuously enhance its core competitiveness through R&D innovation. The establishment of the Drug Research Institute will undoubtedly leave a significant mark in the company's development history.